Podcast Episodes
Back to Search
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Season 7 Episode 359
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but wil…
7 months, 2 weeks ago
Ep. 358 - Europe's biotech challenge
Season 7 Episode 358
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk…
7 months, 2 weeks ago
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
Season 7 Episode 357
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioC…
7 months, 3 weeks ago
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Season 7 Episode 356
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury Thi…
7 months, 4 weeks ago
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Season 7 Episode 355
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on …
8 months ago
Ep. 354 - East-West Summit Takeaways
Season 7 Episode 354
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterp…
8 months, 1 week ago
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
Season 7 Episode 353
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor task…
8 months, 1 week ago
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Season 7 Episode 352
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the …
8 months, 2 weeks ago
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Season 7 Episode 351
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple mye…
8 months, 4 weeks ago
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
Season 7 Episode 350
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. …
9 months ago